CTAD

ctad-logo

8-10 December,2016
San Diego, California

The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2015 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD. Again in 2016 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage.

CTAD 2016 will highlight the latest on trying to get these trials off the ground.

ACNP

ACNP-logo

4-8 December, 2016
Hollywood, Florida

The annual meeting of the American College of Neuropsychopharmacology is one of the world’s leading forums for the exchange of cutting edge scientific information about the brain, behavior, and psychotropic drugs.

CNS Summit

CNS logo

27-30 October 2016
Boca Raton, Florida

CNS Summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. Its mission is to have a positive impact on the success of clinical development programs.

ISCTM

ISCTM-logo

26-27 September 2016
Philadelphia

The International Society for CNS Clinical Trials and Methodology (ISCTM) is a multi-disciplinary independent organization, devoted to promoting advances that address strategic clinical, regulatory, methodological, and policy challenges that arise in the development of therapeutic agents.

Richard Keefe, PhD and Atul Pande, MD will co-chairined an update from

In addition, NeuroCog Trials presented:

  • Cultural Adaptation of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) for Use in the UK and Canada
            Atkins, AS1; Kelly, SE1, Hamby, M1, Roux, P1,  Gonzalez, M1, Madden, J1Stankovic, M1, Keefe, RSE1, 2
  • Rasch Analysis to test the Cross-Cultural Item Equivalence of the Alzheimer’s Disease Assessment Scale-Cognition (ADAS-Cog)
            Khan, A1, 3  Stroescu, I1, Atkins, AS1, Keefe, RSE1, 2
             (1) NeuroCog Trials (Durham, NC), (2) Duke University Medical Center (Durham, NC),
             (3) Nathan S. Kline Institute for Psychiatric Research (Orangeburg, NY)

Triangle Biotech Tuesday

Triangle-Biotech-Tuesday

9 August 2016
Research Triangle Park, 2525 E NC HWY 54, Durham, NC

Triangle Biotech Tuesday is a not-for-profit monthly networking event to connect scientific professionals, facilitate collaborations and foster communications throughout the Research Triangle. There is no set agenda, so we invite you to simply enjoy food, drinks, and to converse with local professionals. This is a great opportunity to expand your professional network and reach across industries.

AAIC 2016

aaic16-logo

22-28 July 2016
Toronto

AAIC is the Alzheimer’s Association International Conference. International investigators, clinicians and care providers share the latest study results, theories and discoveries that will help bring the world closer to breakthroughs in dementia science.

NeuroCog Trials was located at booth 820.

Anzalee Kahn, PhD presented

Assessing the Impact of a Centralized Data Review on the Reliability of the Alzheimer’s Disease Assessment ScaleCognitive (ADASCog)

For more information about our AD/MCI capabilities, navigate here.

DIA 2016

NA_16001_microsite-banner_615x245

26-30 June 2016
Philadelphia

DIA 2016 is the largest global interdisciplinary event that brings together key thought leaders and innovators from industry, academia, regulatory and government agencies, health, patient, and philanthropic organizations from around the globe – and across all disciplines involved in the discovery, development, and life cycle management of health care products.

2016 ASCP Annual Meeting

ASCP-logo

May 30 – June 3, 2016
Scottsdale, AZ

Dr. Richard Keefe and Dr. Brian Saxby will be presenting in the Individual Research Reports panel on Tuesday, May 31st from 4:15 pm – 5:30 pm. Dr Keefe will discuss How Do Key Co-Primary Measures of Functional Capacity Predict Real World Function in schizophrenia? and Dr. Brian Saxby will present data on the Validation of the Tablet-Based Brief Assessment of Cognition (BAC App) for Schizophrenia.

The ASCP (formerly NCDEU) Annual Meeting includes representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry to discuss key aspects of neuropsychiatric drug development.

Diversity Alliance for Science

DA4S

16-18 May 2016
Newark, NJ

This three-day event will will feature government officials, top-level pharmaceutical executives, CEOs of diverse scientific and clinical enterprises, and guest speakers.

5th Biennial Schizophrenia International Research Society Conference

SIRS-logo

2-6 April 2016
Florence, Italy

The Schizophrenia International Research Society Biennial Conference focuses on new drug development and the status of cutting edge basic and translational research in the field of schizophrenia.

Innovations in Testing 2016

Innovations in Testing 2016

Association of Test Publishers

March 20-23
Orlando, FL

 

 

14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy

AAT logo

 

 

 

Advances in Alzheimer Therapy

March 9-12, 2016
Athens, Greece

Leading scientists will discuss new targets and drugs for the treatment of Alzheimer’s disease and novel approaches to current therapy. An oral communication session will be open to young scientists.

 

 

NeuroscienceTrials of the Future: A Workshop

 

National Academy of Medicine

March 3-4, 2016
Washington D.C.

This public workshop, co-chaired by Drs. Richard Keefe and Atul Pande, will bring together key stakeholders to discuss opportunities to improve the integrity, efficiency, and validity of clinical trials for nervous system disorders. Discussion will focus on the development and integration of innovative methods for trial design, execution, and evaluation, with an emphasis on Phase II and Phase III programs. Specific topics addressed will include adaptive trial designs, improved integration of biomarkers, use of wearable and patient monitoring technologies, and regulatory opportunities and challenges facing the field at large.

The full meeting description and agenda are available here.

 

ISCTM 12th Annual Scientific Meeting

ISCTM-logo

February 16-18, 2016
Washington, D.C.

NeuroCog Trials will be presenting three posters:

How do key co-primary measures of functional capacity predict real world function in schizophrenia?

Keefe, RSE1, 2 ; Atkins, AS1; Davis, VG1; Harvey, P3; Narasimhan, M4; Patterson, T5

 (1) NeuroCog Trials (Durham, NC); (2) Duke University Medical Center (Durham, NC); (3) University of Miami Miller School of Medicine (Miami, FL); (4) University of South Carolina School of Medicine (Columbia, SC); (5) University of California, San Diego, School of Medicine (San Diego, CA)

Validation of the Tablet-based Brief Assessment of Cognition (BAC App) for Schizophrenia

Atkins, AS1; Keefe, RSE1, 2 ; Davis, VG1; Tseng, T1; Vaughan, A1;  Harvey, P3; Narasimhan, M4; Patterson, T5

 (1) NeuroCog Trials (Durham, NC); (2) Duke University Medical Center (Durham, NC); (3) University of Miami Miller School of Medicine (Miami, FL); (4) University of South Carolina School of Medicine (Columbia, SC); (5) University of California, San Diego, School of Medicine (San Diego, CA)

Examining effects of language and region on test-retest reliability of the MATRICS Consensus Cognitive test Battery (MCCB)

Georgiades, A1, 2; Davis, VG1; Atkins, AS1; Stroescu, I1; Keefe, RSE1, 2

(1) NeuroCog Trials, Inc. (Durham, NC), (2) Duke University Medical Center, Department of Psychiatry (Durham, NC)

 

Mood Disorders Summit

GME-logo

December 11-12, 2015
Coral Gables, FL, USA

Dr. Richard Keefe, professor of psychiatry, psychology and neuroscience, Duke University Medical Center, NeuroCog Trials, will be presenting:

Cognition and Mood Disorders: The Next Frontier

American College of Neuropsychopharmacology
Annual Meeting

ACNP-logo

December 6-10, 2015
Hollywood, FL

The Annual Meeting of the American College of Neuropsychopharmacology (ACNP) is dedicated to the latest developments in clinical and basic research on brain, behavior, and psycotropic drugs, brain behavior-drug interactions and advances in psychopharmacology presented by internationally distinguished researchers and scientists.

 

Norwegian Neuropsychological Association   Annual Meeting

Norsk Psykolog Forening

November 19-21, 2015
Oslo, Norway

Dr. Richard Keefe, professor of psychiatry, psychology and neuroscience, Duke University Medical Center, NeuroCog Trials, will be presenting:

Cognitive impairment and its clinical relevance in schizophrenia

 Clinical Trials on Alzheimer’s Disease (CTAD)

CTAD

November 5-7, 2015
Barcelona, Spain

Join NeuroCog Trials for the 8th annual CTAD conference in Barcelona.  Our team will be in attendance for the poster session discussing the following topics:

Cultural Adaptation of the TOMMORROW Cognitive Battery in Russia, Switzerland, and Italy

Impact of Expert Data Review and Centralized Scoring on Test-Retest Reliability of the ADAS­-Cog

 

American Translators Association

ATA

November 4-7, 2015
Miami, FL

NCT Linguistics will join the members of the American Translators Association to connect and communicate during an in-depth learning experience with translators working in languages around the world.